NZ600059A - Antibodies against cd38 for treatment of multiple myeloma - Google Patents

Antibodies against cd38 for treatment of multiple myeloma

Info

Publication number
NZ600059A
NZ600059A NZ600059A NZ60005906A NZ600059A NZ 600059 A NZ600059 A NZ 600059A NZ 600059 A NZ600059 A NZ 600059A NZ 60005906 A NZ60005906 A NZ 60005906A NZ 600059 A NZ600059 A NZ 600059A
Authority
NZ
New Zealand
Prior art keywords
seq
set forth
sequence
human
light chain
Prior art date
Application number
NZ600059A
Other languages
English (en)
Inventor
Paul Parren
Yvo Graus
Judith Oprins
Michel De Weers
Martine Van Vugt
Jan Van De Winkel
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Priority to NZ625944A priority Critical patent/NZ625944A/en
Priority claimed from NZ586780A external-priority patent/NZ586780A/en
Publication of NZ600059A publication Critical patent/NZ600059A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ600059A 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma NZ600059A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ625944A NZ625944A (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500429 2005-03-23
US66757905P 2005-04-01 2005-04-01
US69616305P 2005-07-01 2005-07-01
US72856105P 2005-10-20 2005-10-20
NZ586780A NZ586780A (en) 2005-03-23 2006-03-23 Antibodies against CD38 for treatment of multiple myeloma

Publications (1)

Publication Number Publication Date
NZ600059A true NZ600059A (en) 2016-01-29

Family

ID=50644285

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ600059A NZ600059A (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma
NZ625944A NZ625944A (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ625944A NZ625944A (en) 2005-03-23 2006-03-23 Antibodies against cd38 for treatment of multiple myeloma

Country Status (12)

Country Link
KR (1) KR20140033240A (OSRAM)
BE (1) BE2017C062I2 (OSRAM)
DK (1) DK1866338T3 (OSRAM)
ES (2) ES2606762T3 (OSRAM)
HU (2) HUE034962T2 (OSRAM)
LT (2) LT1866338T (OSRAM)
NZ (2) NZ600059A (OSRAM)
PL (1) PL1866338T3 (OSRAM)
PT (2) PT1866338T (OSRAM)
RS (1) RS55442B1 (OSRAM)
SG (1) SG10201610317VA (OSRAM)
UA (2) UA98756C2 (OSRAM)

Also Published As

Publication number Publication date
BE2017C062I2 (OSRAM) 2025-12-03
ES2606762T3 (es) 2017-03-27
LT1866338T (lt) 2017-01-25
SG10201610317VA (en) 2017-02-27
ES2644982T3 (es) 2017-12-01
UA98756C2 (ru) 2012-06-25
HUE030783T2 (en) 2017-06-28
HUE034962T2 (en) 2018-03-28
KR20140033240A (ko) 2014-03-17
LT2567976T (lt) 2017-12-11
PL1866338T3 (pl) 2017-04-28
DK1866338T3 (da) 2017-01-02
NZ625944A (en) 2016-01-29
RS55442B1 (sr) 2017-04-28
UA116520C2 (uk) 2018-04-10
PT2567976T (pt) 2017-10-19
PT1866338T (pt) 2016-12-14

Similar Documents

Publication Publication Date Title
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
TW200720289A (en) Antibodies against CCR5 and uses thereof
NZ598063A (en) Gram-positive bacteria specific binding compounds
NZ605980A (en) Anti-fap antibodies and methods of use
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
FI2155783T4 (fi) Lajien välisesti spesifinen cd3-epsilon-sitoutumisdomeeni
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
NZ599405A (en) Targeted binding agents against b7-h1
WO2010095031A3 (en) Humanized antibodies that bind to cd19 and their uses
NZ595235A (en) Compositions and methods for increasing muscle growth
IL196914A (en) Isolated monoclonal antibodies with sequences of different regions that specifically bind il-31, polynucleotide and expression vectors encoding antibodies, methods for their production and use
NZ715896A (en) Humanized or chimeric cd3 antibodies
WO2006055809A3 (en) Antibodies against vascular endothelial growth factor receptor-1
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
NZ594275A (en) B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2007120693A3 (en) Targeted binding agents directed to upar and uses thereof
WO2008063771A3 (en) Anti-cd20 antibodies and methods of use
NZ600005A (en) Antibodies against human angiopoietin 2
HRP20120759T1 (hr) Bispecifična veziva specifična između vrsta
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
GEP20074222B (en) Antibodies to cd40
EP2471817A3 (en) Humanized antibody molecules specific for IL-31
HRP20130922T1 (hr) U potpunosti humana protutijela protiv humanog 4-1bb (cd137)

Legal Events

Date Code Title Description
AABA Application abandoned
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 23 MAR 2019 BY WATERMARK PATENT AND TRADE MARKS ATTORNEYS

Effective date: 20160504

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2020 BY CPA GLOBAL

Effective date: 20190208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2021 BY CPA GLOBAL

Effective date: 20200206

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2022 BY CPA GLOBAL

Effective date: 20210204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2023 BY CPA GLOBAL

Effective date: 20220204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2024 BY CPA GLOBAL

Effective date: 20230210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250206